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BACKGROUND. Neutrophils and their inflammatory mediators are key pathogenic
components in multiple autoimmune diseases, while their role in human type 1 diabetes
(T1D), a disease that progresses sequentially through identifiable stages prior to the clinical
onset, is not well understood. We previously reported that the number of circulating
neutrophils is reduced in patients with T1D and in presymptomatic at-risk subjects. The aim
of the present work was to identify possible changes in circulating and pancreas-residing
neutrophils throughout the disease course to better elucidate neutrophil involvement in
human T1D.
METHODS. Data collected from 389 subjects at risk of developing T1D, and enrolled in 4
distinct studies performed by TrialNet, were analyzed with comprehensive statistical
approaches to determine whether the number of circulating neutrophils correlates with
pancreas function. To obtain a broad analysis of pancreas-infiltrating neutrophils throughout
all disease stages, pancreas sections collected worldwide from 4 different cohorts (i.e.,
nPOD, DiViD, Siena, and Exeter) were analyzed by immunohistochemistry and
immunofluorescence. Finally, circulating neutrophils were purified from unrelated
nondiabetic subjects and donors at various T1D stages and their transcriptomic signature
was determined by RNA sequencing.
RESULTS. Here, we show that the decline in […]
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BACKGROUND. Neutrophils and their inflammatory mediators are key pathogenic components 
in multiple autoimmune diseases, while their role in human type 1 diabetes (T1D), a disease 
that progresses sequentially through identifiable stages prior to the clinical onset, is not well 
understood. We previously reported that the number of circulating neutrophils is reduced in 
patients with T1D and in presymptomatic at-risk subjects. The aim of the present work was to 
identify possible changes in circulating and pancreas-residing neutrophils throughout the disease 
course to better elucidate neutrophil involvement in human T1D.
METHODS. Data collected from 389 subjects at risk of developing T1D, and enrolled in 4 distinct 
studies performed by TrialNet, were analyzed with comprehensive statistical approaches to 
determine whether the number of circulating neutrophils correlates with pancreas function. To 
obtain a broad analysis of pancreas-infiltrating neutrophils throughout all disease stages, pancreas 
sections collected worldwide from 4 different cohorts (i.e., nPOD, DiViD, Siena, and Exeter) were 
analyzed by immunohistochemistry and immunofluorescence. Finally, circulating neutrophils 
were purified from unrelated nondiabetic subjects and donors at various T1D stages and their 
transcriptomic signature was determined by RNA sequencing.
RESULTS. Here, we show that the decline in β cell function is greatest in individuals with the lowest 
peripheral neutrophil numbers. Neutrophils infiltrate the pancreas prior to the onset of symptoms 
and they continue to do so as the disease progresses. Of interest, a fraction of these pancreas-
infiltrating neutrophils also extrudes neutrophil extracellular traps (NETs), suggesting a tissue-specific 
pathogenic role. Whole-transcriptome analysis of purified blood neutrophils revealed a unique 
molecular signature that is distinguished by an overabundance of IFN-associated genes; despite being 
healthy, said signature is already present in T1D-autoantibody-negative at-risk subjects.
CONCLUSIONS. These results reveal an unexpected abnormality in neutrophil disposition both in 
the circulation and in the pancreas of presymptomatic and symptomatic T1D subjects, implying that 
targeting neutrophils might represent a previously unrecognized therapeutic modality.
FUNDING. Juvenile Diabetes Research Foundation (JDRF), NIH, Diabetes UK.
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Introduction
Neutrophils are key cells in the recognition and elimination of  pathogens, but they also sense self  
components, including products of  sterile tissue damage. Normally, self-recognition contributes to 
tissue repair but, in some circumstances, it can also lead to the release of  highly immunogenic factors 
that can trigger and/or amplify autoimmune pathogenic loops. Neutrophils therefore can contribute to 
the clearance of  acute inflammation, but they may also play a harmful role in chronic inflammatory and 
autoimmune diseases (1). Recent experimental data indicate that neutrophils play a pivotal role in both the 
immunization and the effector phases in systemic lupus erythematosus (SLE) (2, 3), rheumatoid arthritis 
(4, 5), and autoimmune vasculitis (6).
Type 1 diabetes (T1D) is an autoimmune disease characterized by loss of  insulin production and 
reliance on exogenous insulin for survival. Development of  islet autoantibodies (autoAbs) occurs before 
clinical diagnosis, making T1D a predictable disease in an individual with 2 or more autoAbs (7). T1D is 
mainly considered to be a T cell–centered disease and the role of  neutrophils (the most abundant circulating 
immune cell type and the first immune cells to respond to inflammation) in the etiology of  this disease 
in humans has mostly been ignored (8). The contribution of  neutrophils to the pathogenesis of  T1D was 
demonstrated for the first time in the nonobese diabetic (NOD) mouse model, in which self-DNA–anti-
DNA IgG immune complexes formed in the pancreas trigger neutrophil extracellular trap (NET) formation 
and the release of  the cathelicidin peptide CRAMP. These complexes activate plasmacytoid dendritic cells to 
release IFN-α, which is believed to trigger further T cell–mediated autoimmune processes (9). In humans we 
have previously reported that the number of  circulating neutrophils is reduced in patients with T1D as well as 
in presymptomatic at-risk subjects (10) (see supplemental materials for detailed T1D staging; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.122146DS1). This reduction 
was subsequently confirmed independently (11–14). We also reported that neutrophils infiltrate the pancreas 
of  donors with T1D and are not observed in the pancreas of  nondiabetic or T2D donors (10), raising the 
notion that these cells may be playing a pathologic role. The aim of  the present work was to identify possible 
changes in circulating and pancreas-residing neutrophils in T1D throughout the disease course to better 
elucidate neutrophil involvement also in humans. To perform this study, data and samples were collected 
from various donor cohorts and details of  the study design can be found in Table 1 and in the Methods.
Results
Presymptomatic T1D subjects with reduced circulating neutrophil numbers have the poorest β cell function. To 
test whether the number of  circulating neutrophils correlates with pancreas function, we collected data 
from 3 clinical prevention studies performed by TrialNet (see supplemental materials for detailed study 
descriptions). The studies involved 289 presymptomatic at-risk subjects (Supplemental Tables 1 and 2 
for study and donor characteristics). Several metabolic measures (single and composite) collected in 
a 2-hour standard oral glucose tolerance test (OGTT) at study screening (i.e., before any therapeutic 
intervention) were evaluated in relation to the number of  circulating neutrophils measured by com-
plete blood counts (CBCs) (Supplemental Table 3). In these at-risk individuals the number of  circulat-
ing neutrophils significantly correlated with fasting C-peptide, early C-peptide response (30 minute 
– basal C-peptide), and stimulated C-peptide (mean C-peptide AUC) as well as with the composite 
metabolic measures HOMA-β and Index60 but not with any of  the remaining measures (Figure 1A 
and Supplemental Table 4). These correlations were neutrophil specific since significant meaningful 
associations were not observed in relation to lymphocyte counts except for a modest correlation with 
fasting C-peptide and glucose (Figure 1A and Supplemental Table 4).
The number of  circulating neutrophils was significantly influenced by age, sex, and BMI percentile (Sup-
plemental Table 5). These parameters were therefore evaluated in multivariable models with the metabolic 
markers of  interest and we found that fasting and stimulated C-peptide remained significantly associated 
with peripheral neutrophil counts after adjustment for these factors (Supplemental Table 6). Further evalua-
tion of  the metabolic markers adjusting for these parameters (as well as interactions with them), were used in 
the model-building approaches. Significant interactions emerged between fasting C-peptide and age, as well 
as between stimulated C-peptide and BMI in relation to neutrophil counts. Thus, the influence of  fasting 
C-peptide on neutrophil counts was more strongly correlated and influential in older subjects, while that of  
stimulated C-peptide was more strongly associated and influential in those subjects who are overweight or 
obese (Figure 1B; see Supplemental Tables 7 and 8 for estimated model descriptions).
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We emphasize that these data originate from intervention studies in which CBCs were measured at dif-
fering clinical sites and where donor selection was determined by relevant study inclusion criteria (listed in 
Supplemental Table 1). To address this potential bias, we collected analogous data from our local (Milan, 
Italy) TN01 (TrialNet Pathway to Prevention Study) cohort in whom CBC measurements were performed 
at a single clinical site and no inclusion criteria (other than having a relative with T1D) were applied (see 
supplemental materials pertinent study details). A total of  109 presymptomatic subjects with 303 overall 
observations were included in the analysis (see Supplemental Tables 9 and 10 for donor and observation 
characteristics). Given the presence of  repeated measures and the familial relationships between some of  
the donors, linear mixed-effects models were applied. On the basis of  previous analysis of  the TN-interven-
tion cohort, we focused on fasting and stimulated C-peptide and considered the same covariates. In both 
models, neutrophil counts significantly increased with BMI. Fasting C-peptide also had a significantly posi-
tive effect on neutrophil counts and this effect increased with age. Stimulated C-peptide had a similar effect 
on neutrophil counts, but the size effect depended both on age (bigger effects were seen in older people) 
and on sex (males had lower circulating neutrophils) (Figure 1C; see Supplemental Tables 11 and 12 for 
estimated model descriptions).
Overall, these data gathered from 398 presymptomatic at-risk TrialNet donors (for a total of  592 
observations), upon careful and comprehensive statistical analyses that considered several potentially 
confounding factors, indicate that reduced β cell function (as measured by fasting and stimulated C-pep-
tide production after a standard 2-hour OGTT) consistently and significantly correlates with reduced 
circulating neutrophil counts.
Neutrophils releasing NETs infiltrate the pancreas of  presymptomatic and symptomatic T1D subjects. We know, 
from our previous work, that neutrophils infiltrate the pancreas of  organ donors with T1D (10) but it 
remains unclear whether this is limited to the cohort originally examined and whether neutrophils also 
infiltrate the pancreas of  presymptomatic individuals. We therefore analyzed 4 independent pancreas 
cohorts collected worldwide: nPOD (15), DiViD (16), Exeter (17), and Siena (18) (see Supplemental Tables 
13 and 14 for donor and pancreas section characteristics). Immunohistochemical analysis demonstrated, 
for the first time to our knowledge, that pancreas-residing neutrophils can be found in presymptomatic 
autoAb-positive donors (Figure 2A) and confirmed that these cells infiltrate the pancreas of  subjects with 
T1D (Supplemental Figure 1A). To increase our understanding of  tissue-resident neutrophil morphology, 
we performed immunofluorescence analysis upon DNA and myeloperoxidase (MPO) staining in 2 
independent laboratories on frozen, optimal cutting temperature compound–embedded (OCT-embedded) 
(Figure 2B and Supplemental Videos 1 and 2) and on formalin-fixed, parrafin-embedded (FFPE) sections 
(Supplemental Figure 1B). Quantitative analysis of  MPO-positive cells confirmed that pancreas-residing 
neutrophils are more frequent in presymptomatic autoAb-positive and T1D donors than in nondiabetic 
Table 1. Study design
Study Objective Data|Sample origin Donor characteristics n Reference Figure|Table|Video
Correlation between pancreas 
function and CBC measures
TN10, TN18, TN20 AutoAb pos Subjects 289, Observations 289 Figure 1, A and B, Tables S1–S8A
TN01 – Milan Site AutoAb neg&pos Subjects 109, Observations 303 Figure 1C, Tables S9–S12
Neutrophil localization and 
characterization in the pancreas
nPOD nondiabetic Subjects 6, Sections 14
AutoAb pos Subjects 4, Sections 10
T1D Subjects 4, Sections 10
SIENA T1D Subject 1, Sections 3 Figures 2 and 3, Figures S1–S3, 
Tables S12 and S13, Videos 
S1–S4
DiViD T1D Subjects 6, Sections 12
EXETER T1D Subjects 5, Sections 5
Transcriptomic signature of 
circulating (blood-derived) 
neutrophils
Local Cohort nondiabetic Subjects 16
T1D Subjects 5 Figures 4–6, Figures S4–S6, 
Table S14
TN01 AutoAb neg Subjects 13
AutoAb pos Subjects 8
AS indicates Supplemental. TN, TrialNet; AutoAb, T1D autoantibody; pos, positive; neg, negative; CBC, complete blood count.
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donors (Figure 2C). Examination of  pancreatic sections from the Exeter cohort was more complex, likely 
because of  the tissue origin and preservation. The Exeter Archival Diabetes Biobank contains samples 
of  autopsy pancreas having variable degrees of  autolysis (due to nonstandardized conditions of  fixation 
and postmortem processing), which can lead to interpatient variation when studying labile antigens (17). 
However, immunofluorescence analysis of  pancreatic autopsies from 5 T1D subjects all showed neutrophil 
infiltration (Supplemental Figure 2).
The occurrence of  decondensed DNA colocalized with MPO in both frozen OCT-embedded and FFPE 
sections (as highlighted in Figure 2B and Supplemental Figure 1B) suggests the presence of  pancreas-residing 
NETting neutrophils (i.e., releasing NETs). Additional proof  of  tissue-residing NETting neutrophils was 
also obtained by the identification of  decondensed DNA decorated with MPO and citrullinated histones. 
Staining with anti–human citrullinated histone antibodies is known to be cumbersome and highly 
dependent on organ preservation (19, 20). This staining was therefore only possible in a proportion of  
the available pancreas sections (i.e., 21 sections from 13 subjects across the 4 cohorts). Nevertheless, this 
Figure 1. Reduced pancreas β cell function correlates 
with reduced circulating neutrophils. (A) Scatterplot 
and Spearman’s correlation analyses between peripheral 
neutrophil (upper) or lymphocyte (lower) counts and fasting 
C-peptide, early C-peptide response (30-minute – 0-minute 
C-peptide), stimulated C-peptide (mean C-peptide AUC) 
HOMA-β and Index60 collected from TN-intervention studies 
(TN10, TN18, TN20). Each data point represents 1 donor 
(n = 298). Data distribution, Spearman’s rank correlation 
coefficient (r), and P value are shown for each analysis. As 
this is a nonparametric correlation analysis, the regression 
lines could be added. Neutrophil and lymphocyte counts, 
fasting and stimulated C-peptide, and HOMA-β were log 
transformed to perform the analysis, but they are shown 
as original measures. (B) Final linear regression models for 
predicting neutrophil counts on the basis either of fasting or 
stimulated C-peptide with additional consideration for the 
potential effects of age, sex, and BMI percentile as well as 
the respective interactions between said effects are shown. 
The data used are from TN-intervention studies (n = 298) 
and the final models are plotted with the original scale of the 
variables. (C) Final linear mixed-effects models for predicting 
neutrophil counts on the basis of either fasting or stimulated 
C-peptide, when also considering the potential effects of 
age, sex, and BMI percentile as well as interactions with 
them are shown. The data used are from the Milan-TN01 
study (n = 109 subjects; n = 303 observations) and the final 
models are plotted with the original scale of the variables.
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Figure 2. Intact and NETting neutrophils infiltrate the pancreas of presymptomatic and symptomatic T1D donors. (A) One representative image of an 
immunohistochemical (IHC) analysis of a formalin-fixed, paraffin-embedded (FFPE) section (out of 12 total sections analyzed) from an autoAb-positive nPOD 
donor (no. 6197) stained with hematoxylin and anti-MPO (neutrophil-specific) antibody (brown staining). Scale bar: 100 μm. (B) Representative images of 
immunofluorescence (IF) analyses of frozen OCT-embedded nPOD sections (out of 13 total sections analyzed) stained with anti-MPO antibody (green, left 
column) and Hoechst 33342 for DNA detection (white, middle column). Expression signals were then merged (right column). Donor ID and characteristics are 
shown on the left. Images are represented as Z-stacked following projection. Insets were cut (dotted square) and magnified ×1.5 at the bottom of each panel 
and they highlight the occurrence of decondensed DNA colocalized with MPO, which in turn suggests the presence of pancreas-residing NETting neutrophils. 
Scale bars: 20 μm. (C) Quantification of MPO-positive cells on FFPE pancreatic sections analyzed by IHC (empty dots, and green triangles for the Siena cohort) 
and IF (red dots) are shown in box-and-whisker plots as number of cells per squared millimeter. Numbers indicate donor ID. Each symbol represents 1 section 
analyzed (n = 26 donors; n = 34 sections). Comparisons between groups were performed with a linear mixed-effects model followed by post hoc analysis (see 
supplemental methods for details). (D) One representative image of an IF analysis of an FFPE section (out of 22 total sections analyzed) from one DiViD T1D 
donor (no. 5) stained with anti-MPO (green), anti-citrullinated histone H3 (red) antibodies and Hoechst 33342 for DNA detection (white). Scale bars: 10 μm.
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analysis clearly showed that a fraction of  neutrophils infiltrating the pancreas had undergone NETtosis 
(i.e., 54% ± 10% and 50% ± 17% [mean ± SD] of  neutrophils were releasing NETs in autoAb-positive and 
T1D donors, respectively) (Figure 2D and Supplemental Videos 3 and 4).
As we previously reported with regard to T1D donors (10), we hereby noted that neutrophils do not 
specifically localize in close proximity to the β cells even in presymptomatic autoAb-positive subjects, 
but that they are uniformly distributed within vessels and, more significantly, throughout the pancreas 
(Figure 3 and Supplemental Figure 3).
Thus, the data we generated in 2 distinct labs and on sections from 4 different cohorts collected 
worldwide, including living and brain-dead organ donors, indicate that regions of  the pancreas of  
presymptomatic and symptomatic T1D subjects are infiltrated by neutrophils to a varying degree and that 
a proportion of  these cells undergoes NETtosis.
Blood neutrophils of  T1D subjects at all disease stages have a unique molecular signature that is distinguished by 
an overabundance of  IFN-associated genes. Overall, our data indicate that, as T1D develops, neutrophils are 
attracted into the pancreas and that the ensuing reduction in circulating numbers correlates with reduced 
β cell function. To test whether this abnormal T1D neutrophil disposition is confined to the pancreas or 
whether it also applies to the periphery, we purified circulating neutrophils from the blood of  donors at 
various disease stages (see Supplemental Table 15 for donor characteristics) and generated genome-wide 
transcriptional profiles. Differential gene expression analysis revealed a similarity in the transcriptional 
profiles between autoAb-negative, autoAb-positive, and new-onset T1D subjects (Figure 4). Notably, this 
similarity recurred when we applied unsupervised hierarchical clustering of  subjects on the bases of  
the subjects’ transcriptional profiles. Unrelated nondiabetic controls all clustered together (except for 1 
outlier: ctrl-110) while autoAb-negative, autoAb-positive, and new-onset T1D patients formed a single 
and distinct large cluster (Supplemental Figure 4A). Given that age range was not identical between the 
groups of  donors analyzed and that neutrophil purity is key for transcriptomic data (21), both factors 
were taken into account. Of  note, the fundamental trend remained unchanged even after accounting for 
patient age and/or purity of  neutrophil samples (Supplemental Figure 4B).
Pairwise analyses of  differential expression among all the patient groups revealed a large number 
of  genes that differentiated unrelated nondiabetic controls from autoAb-negative, autoAb-positive, and 
new-onset T1D patients. By contrast, only a very limited number of  genes differentiated the at-risk and 
diabetic subject groups from each other (Table 2), but it is likely that more differences between the 3 
donor groups would be detected if  larger sized sample groups were analyzed. These data show that the 
transcriptional signature in purified blood neutrophils is abnormal in T1D subjects and that it is found even 
before seroconversion. At-risk and T1D donors notably shared several of  the genes differentially expressed 
between each of  them and nondiabetic controls, suggesting a high degree of  neutrophil transcriptome 
similarities at all disease stages (Supplemental Figure 4C).
In view of  the fact that there was a high degree of  similarity between the gene expression signa-
tures in neutrophils isolated from at-risk subjects (independent of  autoAb status), we considered that it 
would be appropriate to combine the 2 donor categories (autoAb-negative and -positive subjects) as a 
single at-risk category for subsequent analysis. To identify functional components of  the transcriptional 
Figure 3. Neutrophils infiltrating the pancreas of presymptomatic and symptomatic T1D donors are not merely localized close to β cells. Representative 
images of IHC analyses of FFPE sections stained with hematoxylin and anti-MPO antibody (out of 12 total sections analyzed). Donor ID and characteristics 
are shown at the bottom. Arrows indicate MPO-positive cells (brown), while islets are highlighted by dotted lines (left panel), glucagon staining (middle 
panel), or immune cell infiltration (right panel). Scale bars: 10 μm.
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response during disease development, gene ontology (GO) enrichment analysis was performed on the 
genes differentially expressed between the unrelated nondiabetic controls and the at-risk donors. The 
transcriptional signature recovered in T1D was enriched in genes associated with IFN signaling path-
ways and related immunological responses (Figure 5A). Genes downstream of  both type I IFN-α and 
type II IFN-γ signaling were significantly upregulated in neutrophils purified from T1D at all stages 
Figure 4. Peripheral neutrophil transcriptomic signature from at-risk autoAb-negative, autoAb-positive, and new-onset T1D patients form a single large 
cluster distinct from that of unrelated nondiabetic controls. Heatmap showing 2,058 genes differentially expressed in neutrophils freshly isolated from pediatric 
nondiabetic controls without relatives with T1D (unrelated nondiabetic controls, gray, n = 16), autoAb-negative relatives of patients with T1D (at-risk autoAb nega-
tive, blue, n = 13), autoAb-positive relatives of patients with T1D (at-risk autoAb positive, green, n = 8), and patients with T1D at disease onset (T1D new onset, 
orange, n = 5). Scale bar represents the relative gene expression and ranges from the minimum log expression (0.0) to the maximum log expression (1.0).
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(Figure 5B). All differentially expressed IFN-associated genes were more highly expressed in at-risk and 
T1D patients (Figure 5C), even after the removal of  3 subjects with extremely high values (Supplemen-
tal Figure 5A). These genes were distributed across numerous steps in the IFN signaling pathway, as 
well as downstream of  signaling (Figure 6).
An IFN-inducible transcriptional signature associated with disease has been demonstrated in 
patients with rheumatoid arthritis at onset and before disease development (22) and in patients with 
SLE where neutrophils were the major IFN sensors (3). Of  note, a similar signature was also shown 
in whole blood of  subjects at risk of  developing T1D already before the development of  autoAbs and 
throughout disease onset (23, 24). We compared these published modular IFN signatures with our 
neutrophil-specific transcriptional signature. Our set of  IFN-responsive genes found in purified neutro-
phils showed greater overlap with those generated in children before T1D seroconversion (24) than with 
those generated from purified neutrophils from patients with SLE (Supplemental Figure 5B). This anal-
ysis further supports the concept that genetically predisposed subjects have an abnormal IFN signature 
before T1D seroconversion and that neutrophils may be the bearers of  this signature. Our data agree 
with the belief  that a proinflammatory state affects all T1D family members (regardless of  the presence 
of  autoAbs), and that this effect is likely to be due to underlying genetic risk factors (25). To under-
stand whether this unique neutrophil signature is driven by a common HLA-predisposing genetic back-
ground, we performed HLA genotype analysis on all subjects. The HLA T1D–associated risk alleles 
were more represented in T1D donors at all disease stages than in nondiabetic controls (Supplemental 
Figure 6). However, there was no strong correlation between T1D high-risk HLA carriers and deregu-
lated IFN gene sets (data not shown), thus suggesting that either the aberrant neutrophil signature we 
observed is not genetically imprinted or that other non-HLA T1D susceptibility risk-conferring alleles 
influence gene expression, as shown in a comprehensive genome-wide association study that tested 1 
million genetic variants for association with red cell, white cell, and platelet properties in more than 
100,000 participants (26). Our sample size was, however, insufficient to address the latter.
Discussion
This study suggests that neutrophils may play a previously undisclosed role in human T1D. In 
presymptomatic individuals at risk of  developing T1D, we observed that lower peripheral neutrophil counts 
were associated with worsening β cell function. Histological analysis of  sections of  human pancreases 
collected worldwide from 4 different cohorts revealed that neutrophils accumulate in the pancreas of  T1D 
donors at all disease stages — including in autoAb-positive subjects at risk of  the disease. We also found 
that human pancreas–infiltrating neutrophils can extrude NETs. Finally, transcriptomic analysis of  purified 
circulating neutrophils from T1D donors throughout the disease course uncovered a signature distinct from 
that of  nondiabetic donors and characterized by altered IFN-responsive genes.
The role of  neutrophils in human T1D — a disease that has been considered as mainly T cell mediated 
(27) — has not been explored extensively. Nevertheless, we have reported previously that mild neutropenia 
occurs in patients with T1D as well as in presymptomatic subjects (10) and this is now considered a hallmark of  
human T1D (11–14). Our new findings demonstrate that this peripheral reduction in neutrophils is associated 
with poor endocrine pancreatic function. It remains to be clarified whether neutrophils act directly on the 
endocrine pancreas to exert a negative impact on activity or whether their circulating numbers are influenced 
by other, currently unknown, pathological mechanisms associated with the early stages of  T1D. Nevertheless, 
our demonstration that neutrophils accumulate in the pancreas early during disease development and that 
Table 2. Number of deregulated genes among donor groups
At-risk autoAb neg At-risk autoAb pos T1D new onset
Unrelated nondiabetic controls 1,309 829 981
At-risk autoAb neg 9 1
At-risk autoAb pos 1
T1D new onset
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Figure 5. IFN-inducible gene expression signature characterizes circulating neutrophils during all stages of T1D. (A) The most highly enriched 
terms from Gene Ontology Biological Processes in genes differentially expressed between at-risk subjects and unrelated nondiabetic controls are 
shown (terms shown have significant enrichment threshold of 0.1 for the Benjamini-Hochberg–adjusted P value). (B) Median expression of the 
Molecular Signatures Database (MSigDB) hallmark gene sets for response to IFN-α and IFN-γ, by donor group; points show values for individual 
donor (in the at-risk donor category: red dots represent autoAb-negative subjects, black dots autoAb-positive subjects). To test variation between 
the 3 groups, Kruskal-Wallis test was applied, and results are shown below each IFN set. To test differences between groups the Mann-Whitney 
test was applied (IFN-α: at-risk subjects vs. unrelated nondiabetic controls P = 0.059, T1D new onset vs. unrelated nondiabetic controls P = 0.032, 
T1D new onset vs. at-risk subjects P = 0.41; IFN-γ: at-risk subjects vs. unrelated nondiabetic controls P = 0.0015, T1D new onset vs. unrelated 
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they extrude NETs suggests a direct pathogenic role. This is consistent with evidence that neutrophils and 
NETs also play a pathogenic role in a murine model of  autoimmune diabetes (9). In humans, peripheral 
neutrophils are more susceptible to NETosis in diabetic subjects and NETs are known to impair wound 
healing in diabetes (28). However, to our knowledge, this is the first time that NETs have been found in the 
pancreas of  T1D-autoAb-positive donors and in patients with T1D.
As we reported previously (10), we find that pancreas-residing neutrophils lack a specific peri-islet 
localization and it is of  interest that a similar conclusion was reached for infiltrating pancreatic CD8+ 
T cells by others (29). The pathogenic significance of  this distribution remains to be determined, but we 
hypothesize that the immune cells may infiltrate the entire pancreas, thus creating a generalized state of  
pancreatic inflammation (in which neutrophils play a central role) and that an intrinsic β cell vulnerability 
or fragility may then underpin disease pathogenicity (30).
Many data sets suggest that type I IFNs contribute to the development of  T1D in mouse models (31, 
32) as well as in humans (33–35). Our new data are in accord with this and provide additional evidence 
that neutrophils might represent very effective circulating IFN sensors. To confirm that neutrophils 
were sensing the presence of  an IFN-enriched environment, we attempted to measure type I and type II 
IFNs in the plasma of  those subjects whose neutrophils were used to generate the transcriptomic data. 
Unfortunately, however, due to rapid clearance, detection of  IFNs in the circulation can prove challenging 
(36) and conclusive results were not obtained (data not shown). Nevertheless, we note that Hayday and 
colleagues have demonstrated that the presence of  neutralizing self-reactive antibodies specific for type I 
IFNs is associated with protection against T1D in patients with AIRE mutations and immunopositivity to 
GAD (37), thereby supporting an important pathogenic role for IFNs in human T1D.
Another interesting conclusion from our transcriptomic data concerns the presence of an altered neutrophil-
specific signature in T1D family-related autoAb-negative subjects — of whom only a minority will develop 
T1D (~3%–5%). This finding confirms data reported by Hessner and colleagues who discovered that plasma 
of low-risk subjects (i.e., family-related subjects without high-risk HLA) leads to the most robust induction of  
proinflammatory transcripts and the lowest induction of genes associated with regulatory activity (25). Similarly, 
2 independent studies reported that a type I IFN signature is temporally increased in whole blood of susceptible 
children prior to the development of autoAbs (23, 24). These studies — together with our new data — provide 
a unique insight into the preclinical stages of T1D before seroconversion and also have important experimen-
tal implications; autoAb-negative donors from T1D families should not be considered nondiabetic controls in 
immunological and metabolic studies, as they appear to be distinct from nondiabetic unrelated subjects.
Overall, our data provide evidence that infiltrating neutrophils may contribute to reduced pancreatic 
function and tissue damage in human T1D and that they serve as sensors of  an IFN-rich environment, 
which is known to be highly pathogenic for β cells. Importantly, in addition to generating new mechanistic 
hypotheses, these data suggest that targeting of  neutrophils might represent a previously unrecognized 
therapeutic modality for T1D.
Inevitably, our study also has limitations that should be addressed in further work. For example, it 
remains unclear whether the subjects with the lowest peripheral neutrophil counts are those with the highest 
extent of  pancreatic neutrophil infiltration. Verification of  this proposition remains challenging, as it is 
currently difficult to collect pancreas biopsies and blood neutrophil counts from the same subjects. Another 
important issue is to understand how NETs are formed in the pancreas and to confirm whether and how 
they contribute to tissue damage. Studies are currently ongoing to characterize the proteome of  pancreatic 
NETs to determine the nature of  the externalized proteins and immunostimulatory molecules that may 
promote aberrant immune responses and the pathogenesis of  human T1D, as happens in other autoimmune 
diseases (3, 4). Finally, our observation that autoAb-negative subjects already display a distinct neutrophil 
signature suggests that certain risk-conferring alleles may influence gene expression to create a fertile field 
on which additional hits may then promote disease development. This is an interesting hypothesis that will 
require confirmation via a dedicated genotype/phenotype study employing a larger data set.
nondiabetic controls P = 0.032, T1D new onset vs. at-risk subjects P = 0.71). (C) Heatmap showing the 39 IFN-related genes differentially expressed 
in neutrophils freshly isolated from pediatric nondiabetic controls without relatives with T1D (unrelated nondiabetic controls, gray, n = 16) versus 
relatives of patients with T1D who are either autoAb negative or positive (at risk, green, n = 21). Patients with T1D at disease onset are shown for 
comparison (T1D new onset, orange, n = 5). Scale bar represents the relative gene expression and ranges from the minimum log expression (0.0) to 
the maximum log expression (1.0).
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All in all, on the basis of  the current evidence, our data should encourage additional studies to clarify 
further the role of  neutrophils in human T1D pathogenesis.
Methods
Study design
An overview of  the study design is presented in Table 1.
Sample sizes: β cell function and CBC measures analysis with data of  TrialNet-intervention Studies (TN10, 
TN18, and TN20). This analysis utilized participants in 3 separate prevention trials in at-risk subjects for 
T1D. The overall evaluable number of  subjects available for our analyses was n = 289, and for those 
analyses that included BMI percentile, which was only available on 2 trials, the sample size was n = 210. 
Our primary models to analyze the impact of  metabolic factors on neutrophil or lymphocyte counts 
were based on multivariable generalized linear regression models. Even for the more restricted models 
with n = 210 subjects and adjusting for 3 clinical covariates in the model, we had 80% power to detect a 
multiple squared partial correlation coefficient (ρ2) for the metabolic marker of  interest that is approxi-
mately 0.13 over the null-hypothesis value, corresponding to a moderate effect size based on Cohen’s 
criteria. This also accounted for a 0.05 type I error constraint. Pairwise analyses of  correlation coeffi-
cients between neutrophil or lymphocyte counts and metabolic markers of  interest also were conducted. 
Here with n = 289 subjects and a type I error constraint of  0.05, we had at least 80% power to detect a 
correlation coefficient of  0.16 versus the null hypothesis of  0 using a 2-sided test.
β Cell function and CBC measures analysis with data of  Milan-TN01 Study. The sample includes all patients 
with available information on the variables considered in the analysis. The data consist of  303 observations 
gathered from 109 subjects. We performed a power analysis for all the tests of  the coefficients in the final 
models and for almost all tests we obtained a power higher than 0.9.
Figure 6. The IFN pathway is active during all stages of T1D. Pathway diagram was constructed from the “Influenza A pathway” (KEGG PATHWAY 
Database hsa05164) and literature on IFN-related genes (described in detail in the supplemental methods section). Dysregulated transcripts are shaded in 
green (influenza pathway) or in red (IFN-related genes).
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.122146
C L I N I C A L  M E D I C I N E
RNA sequencing data analysis. For RNA sequencing (RNA-seq) data analyses, samples from 42 individu-
als were obtained and included 16 nondiabetic healthy controls, 13 autoAb-negative and 8 autoAb-positive 
relatives of  T1D patients, and 5 recently diagnosed T1D patients.
Data exclusion: β cell function and CBC measures analysis with data of  TrialNet-intervention Studies. In the 
cohort of  participants in the 3 prevention trials, as noted in this study, we excluded 30 subjects who had 
enrolled in 1 of  the 3 included trials. Of  these 30 excluded subjects, 20 had CBC measures that were flagged 
for review and were currently undergoing quality control, and 10 subjects did not yet have their baseline 
CBC measures submitted. Thus, of  the 319 enrolled participants across the trials, 289 (90.6%) were includ-
ed in the analyses presented in this study.
β Cell function and CBC measures analysis with data of  Milan-TN01 Study. In the analysis of  the Milan-
TN01 cohort, few observations were removed for the estimation of  the mixed models, because they were 
outliers for the model.
RNA-seq data analysis. One sample was removed because genetic data indicated that it was incorrectly 
identified. Three additional samples showed anomalous values — analyses were run with and without 
those samples to determine sensitivity of  results to their inclusion.
Replication
β Cell function and CBC measures analysis. In the estimation of  the models with the data of  the Milan-TN01 
cohort, we enhanced the robustness of  the results by removing from the analysis few observations that were 
outliers for the models.
RNA-seq data analysis. RNA-seq results have not been replicated. Insufficient samples were available to 
split the data into training and test sets. A number of  tests were conducted to determine sensitivity of  results 
to outlier samples and/or analytical assumptions — these are described in the main text and the Methods.
Randomization
The study of  the Milan-TN01 data and RNA-seq data is retrospective and not all the analyses regard a 
comparison among groups. When this was the case, the groups were defined based on disease state and 
family history of  disease, so randomization was not applicable. Covariates that could have influenced the 
response variable (such as patient age and sex and, for RNA-seq data, the purity of  samples) were evaluated 
in the analysis (details in main text and Methods). For the data associated with the prevention TrialNet 
trials, these are randomized trials, but since they are ongoing and still in follow-up for their endpoints, 
our focus was only on the cross-sectional pretreatment data on these subjects. As such, randomization 
approaches and assignments were not applicable to these analyses.
Blinding
Regarding the collection of  RNA-seq data, this is not predictably influenced by the person collecting the 
data; hence, blinding during the data collection was not necessary. For clinical data, groups were pres-
ent only in the data of  pancreas images and the blindness of  the group was not possible in the collection 
of  the data. In both cases, data analysis involved comparison of  groups, which required knowledge of  
the group identities.
Composite measures of β cell function and T1D disease risk
HOMA-β. The homeostatic model assessment (HOMA) is a method for assessing β cell function and insu-
lin resistance from basal (fasting) glucose and insulin or C-peptide concentrations. The equation for the 
HOMA-β model is, β cell function (%) = 20 × fasting insulin (μIU/ml)/(fasting glucose [mmol/l] − 3.5). 
This model was built up assuming that normal-weight subjects aged less than 35 years have 100% β cell 
function (38).
Index60. The T1D diagnostic Index60 — a metabolic index — was developed from 2-hour OGTT 
using the log fasting C-peptide, 60-minute C-peptide, and 60-minute glucose: Index60 = 0.3695 × (log 
fasting C-peptide) + 0.0165 × (60-minute glucose) – 0.3644 × (60-minute C-peptide). An OGTT with an 
Index60 of  2.0 represents a point of  transition from prediction to a virtual indication of  T1D develop-
ment in autoAb-positive relatives of  patients with T1D (the higher the Index60, the higher the risk of  
disease development) (39).
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The human pancreas samples
Pancreas sections were collected from 4 distinct cohorts.
nPOD cohort. Following acquisition of  informed research consent, human pancreases were obtained 
from deceased organ donors in the USA and shipped to the Network for Pancreatic Organ Donors with 
Diabetes (nPOD) program at the University of  Florida for processing, following standardized procedures. 
Pancreas donors used in this study included T1D patients, nondiabetic autoAb-positive subjects, and 
nondiabetic controls. Pancreas recovery and transport meet transplant-grade criteria. Frozen OCT-
embedded and FFPE tissues were used (15).
Siena cohort. Whole pancreas was obtained from 1 multiorgan donor with T1D and it was processed 
according to nPOD standard operating procedures and with the approval of  the Tuscany region 
transplantation network based on the Institutional Review Board (IRB) of  the University of  Pisa (18). 
FFPE sections were used for immunohistochemical investigations.
DiViD cohort. Adults with newly diagnosed T1D were invited to participate in the DiViD study. 
The study was approved by the Government’s Regional Ethics Committee (16). After oral and written 
information from the diabetologist and the surgeon separately, they consented to participate in the trial. 
Resection of  the pancreatic tail was performed 3–9 weeks after diagnosis of  T1D. The biopsy samples 
were processed under sterile conditions and immediately divided into multiple smaller pieces; FFPE tissue 
blocks were prepared simultaneously.
Exeter Archival Diabetes Biobank. This comprises a large collection of  pancreas samples from across 
the United Kingdom originally compiled by Foulis (40) but now held at the University of  Exeter (17). 
Pancreases were from patients with recent-onset T1D and were mainly recovered postmortem. They 
represent a historical collection dating from the 1960s to the 1980s and were processed and fixed by 
various methods according to the location. All samples were used with ethical permission from the West of  
Scotland Research Ethics Committee (ref: 15/WS/0258).
Details of  pancreas donors in each cohort can be found in Supplemental Tables 13 and 14.
Pancreas immunohistochemical and immunofluorescence analysis
FFPE pancreatic sections (5 μm thickness) were analyzed as briefly follows. After deparaffinization and 
rehydration, sections were incubated with Tris-buffered saline (TBS, Sigma-Aldrich) supplemented with 
3% H2O2 to block endogenous peroxidases (only for immunohistochemical experiments) and with TBS 
supplemented with 3% bovine serum albumin (BSA, Sigma-Aldrich) to reduce nonspecific reactions. 
Antigen retrieval was performed with 10 mM citrate buffer, pH 6.0.
For immunohistochemical analysis, sections were incubated with rabbit polyclonal anti–human MPO 
(Abcam, ab45977) and swine polyclonal anti-rabbit IgG-HRP (DAKO, P0217) as secondary antibody. MPO 
signal was detected with 3,3′-diaminobenzidine (DAB Quanto, ThermoFisher Scientific, TA-060-HDX). 
Sections were then incubated with Mayer’s hematoxylin solution (Sigma-Aldrich) to counterstain nuclei, 
dehydrated, and mounted with Eukitt (Bio-Optica). Sections from the Siena cohort were also incubated 
with mouse monoclonal anti–human glucagon (R&D Systems, clone 181402, MAB1249) and goat anti-
mouse IgG–alkaline phosphatase (ThermoFisher Scientific, 31320) as secondary antibody. Glucagon signal 
was detected with Liquid Fast Red (ThermoFisher Scientific, TA-060-AL) supplemented with levamisole 
endogenous alkaline phosphatase inhibitor (DAKO, Agilent Technologies, X3021).
For immunofluorescence analysis, sections were incubated with rabbit polyclonal anti–human MPO 
(Abcam) and mouse anti–citrullinated histone H3 (anti-CitH3; citrulline R2 + R8 + R17, clone 7C10, 
LifeSpan Biosciences, LS-C144555) antibodies and with goat anti-rabbit IgG Alexa Fluor 488 (Molecular 
Probes, ThermoFisher Scientific, A11034) and goat anti-mouse IgG Alexa Fluor 594 (Molecular Probes, 
ThermoFisher Scientific, A11032) as secondary antibodies. nPOD sections were also stained with 
polyclonal guinea pig anti-glucagon antibody (LifeSpan Biosciences, LS-C20275) and goat anti-guinea pig 
IgG Alexa Fluor 647 (Molecular Probes, ThermoFisher Scientific, A21450) as secondary antibody. DNA 
was counterstained with Hoechst 33342 (ThermoFisher Scientific, 62249). Finally, sections were mounted 
using Vectashield (Vector Laboratories, H1000) mounting medium.
OCT-embedded tissues (5 μm thickness) were methanol/acetone (1:1, –20°C) fixed, then blocked (PBS 
supplemented with 1% denatured BSA) and incubated with primary antibodies: mouse monoclonal anti-
MPO (Bio-Rad, clone 4A4, 0400-0002) and polyclonal rabbit anti-CitH3 (citrulline R2 + R8 + R17, Abcam, 
ab5103). Sections were washed and incubated with the proper secondary antibodies: goat anti-mouse IgG 
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(H+L) Alexa Fluor 488 (Jackson ImmunoResearch, 115-545-003) and goat anti-rabbit IgG (H+L) Alexa 
Fluor 546 (ThermoFisher Scientific, A11035). DNA was counterstained with Hoechst 33342. Sections were 
mounted on slides with homemade Mowiol mounting medium (glycerol, G5516; Mowiol 4-88, 81381; and 
Dabco 33-LV, 290734, Sigma-Aldrich).
Library preparation and RNA-seq
The cDNA library was prepared using a NEBNext Ultra RNA Library Prep Kit for Illumina (New 
England Biolabs) following the manufacturer’s instructions. Samples were then purified (AMPure XP 
Beads, Beckman Coulter) and enriched with PCR to create the final cDNA library. The quality of  
the cDNA libraries was assessed using an Agilent Technologies 2100 Bioanalyzer. The libraries were 
hybridized to the flow cell and cluster was generated by bridge amplification (TruSeq SBS Kit v3-HS, 
Illumina). Single-end sequencing was performed using the Illumina Hiseq-2500 platform (41). RNA-seq 
data analysis is explained in detail in the supplemental materials and methods section.
Statistics
Pancreas function and CBC measures analysis. All measures were evaluated using graphical and analytical 
exploratory analyses to assess distribution patterns and identify the need for transformations. Metabolic 
markers that required a log-based transformation were transformed by taking the log of  the marker plus 
the constant value of  1 [i.e., log(x + 1)]. Neutrophil and lymphocyte counts were also log transformed. 
In all the analyses, BMI percentiles were calculated using the R package childsds (https://github.com/
mvogel178/childsds/wiki). For the TN prevention studies, the US CDC reference values were used (cdc.
ref), and for the Italian subjects an Italian reference cohort was used (italian.ref). BMI percentiles and age 
were considered in the analyses only as continuous variables.
For the cross-sectional baseline data in the 3 TN prevention trials, data were summarized across 
and within studies, and χ2 tests and Kruskal-Wallis tests were used to assess differential distributions of  
categorical and continuous measures, respectively, between studies. Scatterplots were used to evaluate 
relationships between continuous measures and correlations were assessed using nonparametric 
Spearman’s rank correlation coefficients and tests. Multivariable generalized linear regression models 
were used to evaluate relationships of  each of  the clinical and metabolic markers on neutrophil and 
lymphocyte counts. Multivariable models were evaluated for each metabolic marker and adjusted for 
age, sex, and BMI percentile along with interactions of  each of  these factors with the metabolic marker. 
Variable selection was done using a composite approach of  backward selection as well as Furnival 
and Wilson’s leaps and bounds method for all subsets regression analyses (R package leaps). In the 
longitudinal cohort of  Italian subjects followed through the TN01 PTP study, multivariable analyses 
were performed using linear mixed-effects models, since the data consist of  repeated measurements of  
the same subjects with some subjects belonging to the same family. Random effects were accordingly 
defined nested by family and by subject. As in the analysis of  the other cohort, the effect of  each 
metabolic marker on the neutrophil counts was evaluated separately and accounting for the possible 
effects of  age, sex, BMI percentile and the interactions between these variables with the metabolic 
marker. Final models were obtained using a backward selection procedure. All statistical analyses 
were performed using R 3.4.0 and R 3.4.1 (http://www.R-project.org/). Differences were considered 
significant with P < 0.05.
Pancreas images analysis. Comparisons were carried out using linear mixed-effects model followed by 
a post hoc analysis. P values were adjusted for multiple comparisons with Bonferroni’s correction. All 
statistical analyses were performed using R 3.4.0 and R 3.4.1. Differences were considered significant 
with P < 0.05.
Data and materials availability
RNA-seq data were deposited in the NCBI’s Gene Expression Omnibus (GEO) database under accession 
number GSE110914 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110914).
Custom R codes used to analyze RNA-seq data are available at GitHub (https://github.com/
mjdufort/Battaglia_T1D_neutrophils).
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Study approval
The protocols and consent documents were approved by appropriate independent ethics committees 
or IRBs. All participants (or parents) provided written, informed consent; in addition to their parents 
providing consent, participants younger than 18 years of  age signed a study assent form.
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